Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic

Q3 Medicine Journal of Interventional Medicine Pub Date : 2022-11-01 DOI:10.1016/j.jimed.2022.09.004

Guo Yuan How, Uei Pua

{"title":"Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic","authors":"Guo Yuan How, Uei Pua","doi":"10.1016/j.jimed.2022.09.004","DOIUrl":null,"url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is the second most lethal tumour, with therapies broadly divided into curative and palliative intent. Unfortunately, the majority of HCCs were found to be unresectable at diagnosis. Advances in novel loco-regional therapies have given patients with unresectable HCC a vital chance for disease control and survival. However, the COVID-19 pandemic has greatly shaped and impacted treatment protocols and delivery for HCC patients. This review article aims to describe the impact of the COVID-19 pandemic on the delivery of loco-regional treatment modalities for HCC and compare treatment trends between the pre -pandemic and pandemic eras. Treatment of HCC involves complex collaboration between clinical professionals within their local and global healthcare institutions. The COVID-19 pandemic has had a profound impact on the treatment of HCC. The delivery of loco-regional treatment for HCC will need to adapt to each healthcare system's unique structure.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":"5 4","pages":"Pages 180-183"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/c0/main.PMC9751215.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Interventional Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2096360222000540","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is the second most lethal tumour, with therapies broadly divided into curative and palliative intent. Unfortunately, the majority of HCCs were found to be unresectable at diagnosis. Advances in novel loco-regional therapies have given patients with unresectable HCC a vital chance for disease control and survival. However, the COVID-19 pandemic has greatly shaped and impacted treatment protocols and delivery for HCC patients. This review article aims to describe the impact of the COVID-19 pandemic on the delivery of loco-regional treatment modalities for HCC and compare treatment trends between the pre -pandemic and pandemic eras. Treatment of HCC involves complex collaboration between clinical professionals within their local and global healthcare institutions. The COVID-19 pandemic has had a profound impact on the treatment of HCC. The delivery of loco-regional treatment for HCC will need to adapt to each healthcare system's unique structure.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19大流行期间肝细胞癌局部区域治疗的影响和交付

肝细胞癌(HCC)是第二大致死性肿瘤，其治疗方法大致分为治疗性和姑息性两种。不幸的是，大多数hcc在诊断时发现是不可切除的。新的局部-区域治疗方法的进展为不可切除的HCC患者提供了疾病控制和生存的重要机会。然而，COVID-19大流行极大地塑造和影响了HCC患者的治疗方案和交付。这篇综述文章旨在描述COVID-19大流行对HCC局部-区域治疗方式的影响，并比较大流行前和大流行时期的治疗趋势。HCC的治疗涉及当地和全球医疗机构的临床专业人员之间复杂的合作。COVID-19大流行对HCC的治疗产生了深远影响。肝癌局部-区域治疗的提供将需要适应每个医疗保健系统的独特结构。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊